This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-29 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
This resulted in the creation of the NOD-scid mice which lacked T cells, B cells, and NK cells. This mouse model permitted for a slightly higher level of human cell reconstitution. Nevertheless, a major breakthrough in this field came with the introduction of the mutant IL-2 receptor (IL2rg) gene in the NOD-scid model. This accounted for the creation of the NOD-scid-γcnull mice (NCG, NSG or NOG) models which were found to have defective signaling of interleukins IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Researchers evolved this NSG model by knocking out the RAG1 and RAG2 genes (recombination activation genes), resulting into the RAGnull version of the NSG model that was devoid of major cells of the immune system including the natural killer cells, B lymphocytes and T lymphocytes, macrophages and dendritic cells, causing the greatest immunodeficiency in mice models so far. The limitation with this model was that it lacked the human leukocyte antigen. In accordance to this limitation, the human T cells when engrafted in the mice, failed to recognize human antigen-presenting cells, which consequated in defective immunoglobulin class switching and improper organization of the secondary lymphoid tissue. To circumvent this limitation, the next development came with the introduction of transgenes encoding for HLA I and HLA II in the NSG RAGnull model that enabled buildout of human T-lymphocyte repertoires as well as the respective immune responses. Mice with such human genes are technically human-animal hybrids.
== Further reading == Craigie, W.A.; Bradley, H. (1914). "Realgar". In Sir James, A.H. Murray (ed.). A New English Dictionary on Historical Principles. Clarendon Press at Oxford. p. 202 – via archive.org. William Mesny (1899). Mesny's Chinese Miscellany. A Text Book of Notes on China and the Chinese. Vol. III. Shanghai. p. 251. William Mesny (1905). Mesny's Chinese Miscellany. A Text Book of Notes on China and the Chinese. Vol. IV. Shanghai. pp. 425–426.
=== United States === In the United States, semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. In combination with a reduced-calorie diet and increased physical activity, semaglutide (as Wegovy) is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and who are either obese or overweight; to reduce excess body weight and maintain weight reduction long term in obese individuals twelve years of age or older, or for overweight adults with at least one weight-related comorbid condition. In August 2025, the Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of noncirrhotic metabolic-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. In October 2025, the FDA further expanded the indication for semaglutide (as Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.
. Rate of electron capture dissociation not only depends on the frequency of ion–electron fragmentation reactions but also on the number of ions in an ion–electron interaction volume. Electron current density and cross-section of ECD is directly proportional to fragmentation frequency. An indirectly heated dispenser cathode used as an electron source results in larger electron current and larger emitting surface area.
=== Pharmacodynamics === Loratadine is a tricyclic antihistamine, which acts as a selective inverse agonist of peripheral histamine H1 receptors. The potency of second generation histamine antagonists is (from strongest to weakest) desloratadine (Ki 0.4 nM) > levocetirizine (Ki 3 nM) > cetirizine (Ki 6 nM) > fexofenadine (Ki 10 nM) > terfenadine > loratadine. However, the onset of action varies significantly and clinical efficacy is not always directly related to only the H1 receptor potency, as the concentration of free drug at the receptor must also be considered. Loratadine also shows anti-inflammatory properties independent of H1 receptors. The effect is exhibited through suppression of the NF-κB pathway, and by regulating the release of cytokines and chemokines, thereby regulating the recruitment of inflammatory cells.
Sources: en.wikipedia.org
The Global Carbon Budget 2021 concludes that fossil CO2 emissions rebounded by around +4.8% relative to 2020 emissions – returning to 2019 levels, identifies three major issues for improving reliable accuracy of monitoring, shows that China and India surpassed 2019 levels (by 5.7% and 3.2%) while the EU and the US stayed beneath 2019 levels (by 5.3% and 4.5%), quantifies various changes and trends, for the first time provides models' estimates that are linked to the official country GHG inventories reporting, and shows that the remaining carbon budget at 1. Jan 2022 for a 50% likelihood to limit global warming to 1.5 °C is 120 GtC (420 GtCO2) – or 11 years of 2021 emissions levels. Scientists propose and preliminarily evaluate a likely transgressed planetary boundary for green water in the water cycle, measured by root-zone soil moisture deviation from Holocene variability. A study published one day earlier integrates "green water" along with "blue water" into an index to measure and project water scarcity in agriculture for climate change scenarios. 27 April A lineage of H3N8 bird flu is found to infect humans for the first time, with a case reported in the Henan province of China. Months earlier, H5 strain bird flu viruses (HPAIv) have been detected in Canada and the US. A study extends global assessments of shares of species threatened by extinction with reptiles, which often play functional roles in their respective ecosystems, indicating at least 21% are threatened by extinction.
The high pressure is necessary to achieve a constant flow rate for reproducible chromatography experiments. Depending on the partitioning between the mobile and stationary phases, the components of the sample will flow out of the column at different times. The column is the most important component of the LC system and is designed to withstand the high pressure of the liquid. Conventional LC columns are 100–300 mm long with an outer diameter of 6.4 mm (1/4 inch) and an internal diameter of 3.0–4.6 mm. For applications involving LC–MS, the length of chromatography columns can be shorter (30–50 mm) with 3–5 μm diameter packing particles. In addition to the conventional model, other LC columns are the narrow bore, microbore, microcapillary, and nano-LC models. These columns have smaller internal diameters, allow for a more efficient separation, and handle liquid flows under 1 ml/min (the conventional flow-rate). In order to improve separation efficiency and peak resolution, ultra performance liquid chromatography (UHPLC) can be used instead of HPLC. This LC variant uses columns packed with smaller silica particles (about 1.7 μm diameter) and requires higher operating pressures in the range of 310000 to 775000 torr (6000 to 15000 psi, 400 to 1034 bar).
=== The El Ballouti clan === The El Ballouti clan is based in Antwerp, Belgium and led by drug lord Othman El Ballouti. Originally from Al Hoceïma, Othman grew up in the district of Borgerhout, and from a very early age he regularly visited the Port of Antwerp. With the goal of never getting caught by the police, he trafficked thousands of euros in narcotics every day. The newspaper De Volkskrant describes: "Othman climbed the containers and knew how to calculate very well. He quickly stopped climbing the containers by establishing his own gang who did the climbing instead." Othman later on emigrated to Dubai, where he acquired 4 Villas. He also owns an apartment in the famous Address Residence Sky View which is worth 1.5 million euros, alongside six other luxury homes with a total value of around €8.5 million. This information was published by the OCCRP (Organised Crime and Corruption Reporting Project) after he escaped during an arrest at the Zaventem airport in Brussels, in 2016. The Belgian authorities discovered that Othman El Ballouti has a net worth of at least €100 million, a number that ranks him amongst the richest Belgians in the country. The El Ballouti clan is now considered as one of the largest drug trafficking networks in Belgium, and they are also considered to be one of the 5 Moroccan drug clans who control the cocaine trade in the port of Antwerp.
=== Single gene disorders === Autosomal dominant and recessive single gene disorders which have been diagnosed prenatally by analysing paternally inherited DNA include cystic fibrosis, beta thalassemia, sickle cell anemia, spinal muscular atrophy, and myotonic dystrophy. Prenatal diagnosis of single gene disorders which are due to an autosomal recessive mutation, a maternally inherited autosomal dominant mutation or large sequence mutations that include duplication, expansion or insertion of DNA sequences is more difficult. In cffDNA, fragments of 200 – 300 bp length involved in single gene disorders are more difficult to detect. For example, the autosomal dominant condition, achondroplasia is caused by the FGFR3 gene point mutation. In two pregnancies with a fetus with achondroplasia was found a paternally inherited G1138A mutation from cffDNA from a maternal plasma sample in one and a G1138A de novo mutation from the other. In studies of the genetics of Huntington's chorea using qRT-PCR of cffDNA from maternal plasma samples, CAG repeats have been detected at normal levels (17, 20 and 24). cffDNA may also be used to diagnose single gene disorders. Developments in laboratory processes using cffDNA may allow prenatal diagnosis of aneuploidies such as trisomy 21 (Down syndrome) in the fetus.
Sources: en.wikipedia.org
=== June === 21 June – Ahead of the unfolding secret payment scandal, the Director General of RTÉ, Dee Forbes, was suspended from her employment by the RTÉ Board, and later issued a statement defending her record. 22 June The postal service An Post moved from its historic headquarters in the General Post Office building on O'Connell Street in Dublin to new premises at North Wall Quay. RTÉ admitted that it paid its top presenter Ryan Tubridy €345,000 more than publicly declared between 2017 and 2022, in what the chair of its board said was a "serious breach of trust with the public". 24 June – All 30 remaining Argos retail stores in Ireland closed permanently. 25 June – Phase 5a of the BusConnects transport infrastructure programme was launched in Dublin 26 June – Dee Forbes resigned as Director-General of RTÉ with immediate effect, following ongoing controversy over undisclosed payments to broadcaster Ryan Tubridy.
Free nerve ending A type of unencapsulated nerve ending that detects pain, temperature, and crude touch. These are the most common type of cutaneous receptors. Frontal lobe A region of the cerebral cortex involved in decision-making, planning, motor function, problem-solving, and aspects of personality. Located at the front of each cerebral hemisphere. Frontal eye fields A region in the frontal lobe involved in voluntary eye movements and visual attention. It plays a role in saccadic control and visual tracking. Functional connectivity A measure of how different brain regions interact during rest or tasks, often assessed using fMRI or EEG by examining correlations in activity over time. Functional magnetic resonance imaging (fMRI) A neuroimaging technique that measures brain activity by detecting changes in blood oxygenation (BOLD signal). It is used to study brain function in real time. Fusiform gyrus A brain region located in the temporal and occipital lobes involved in high-level visual processing, including facial recognition and object categorization. Fusiform face area (FFA) A specialized part of the fusiform gyrus that responds selectively to faces. It is often studied in the context of prosopagnosia (face blindness) and visual expertise.
In 2000, the number of unincorporated areas was 295, with a total area of 4,890.33 square kilometres (1,888.17 sq mi). However, the unincorporated areas are continually being incorporated into neighboring municipalities, wholly or partially, most frequently in Bavaria.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.